Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BNC003
MIFTS: 58

Bone Cancer

Categories: Bone diseases, Cancer diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bone Cancer

About this section

MalaCards integrated aliases for Bone Cancer:

Name: Bone Cancer 12 42 15
Malignant Bone Neoplasm 12 17 71
Bone Carcinoma 12 15 71
Bone Neoplasms 74 43 71
Bone Neoplasm 12 17
Malignant Neoplasm of Bone 12
Malignant Osseous Tumor 12
Malignant Bone Tumour 12
Osteosarcoma of Bone 71
Osteogenic Neoplasm 71
Ca - Bone Cancer 12
Neoplasm of Bone 12
Osseous Tumor 12
Bone Tumour 12

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Bone diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:184 DOID:2762
MeSH 43 D001859
NCIt 49 C36082 C9343
SNOMED-CT 67 126537000
UMLS 71 C0005967 C0279530 C0585442 more
Sources

Summaries for Bone Cancer

About this section
MedlinePlus : 42 Cancer that starts in a bone is uncommon. Cancer that has spread to the bone from another part of the body is more common. There are three types of bone cancer: Osteosarcoma - occurs most often between ages 10 and 19. It is more common in the knee and upper arm. Chondrosarcoma - starts in cartilage, usually after age 40 Ewing's sarcoma - occurs most often in children and teens under 19. It is more common in boys than girls. The most common symptom of bone cancer is pain. Other symptoms vary, depending on the location and size of the cancer. Surgery is often the main treatment for bone cancer. Other treatments may include amputation, chemotherapy, and radiation therapy. Because bone cancer can come back after treatment, regular follow-up visits are important. NIH: National Cancer Institute

MalaCards based summary : Bone Cancer, also known as malignant bone neoplasm, is related to osteogenic sarcoma and bone marrow cancer, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Bone Cancer is TNFSF11 (TNF Superfamily Member 11), and among its related pathways/superpathways are ERK Signaling and Cytokine Signaling in Immune system. The drugs Pregabalin and Immunoglobulins, Intravenous have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and prostate, and related phenotypes are growth/size/body region and behavior/neurological

Disease Ontology : 12 A connective tissue cancer that is located in bone and is characterized by uncontrolled cellular proliferation that destroys normal bone tissue.

Wikipedia : 74 A bone tumor is a neoplastic growth of tissue in bone. Abnormal growths found in the bone can be either... more...

Sources

Related Diseases for Bone Cancer

About this section

Diseases in the Bone Cancer family:

Primary Bone Cancer

Diseases related to Bone Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 596)
# Related Disease Score Top Affiliating Genes
1 osteogenic sarcoma 33.5 TP53 TNFSF11 MMP9 IL6 CYCS CDKN2A
2 bone marrow cancer 33.3 TP53 TNFSF11 MIR9-1 MIR21 IL6 CCND1
3 bone squamous cell carcinoma 33.2 TP53 MMP9 EGFR CDKN2A CCND1
4 li-fraumeni syndrome 33.0 TP53 ESR1 EGFR CDKN2A
5 bone sarcoma 33.0 TP53 SERPINA3 MTAP MIR9-1 MIR21 IL6
6 keratocystic odontogenic tumor 31.4 TP53 TNFSF11 MMP9 CCND1
7 bone disease 31.4 TNFSF11 SERPINA3 MMP9 IL6 ESR1 CCL2
8 bone resorption disease 31.3 TNFSF11 SERPINA3 IL6 ESR1 BMP2
9 pain agnosia 31.3 TRPV1 IL6 CNR1
10 osteomyelitis 31.2 TNFSF11 IL6 CCL2 BMP2
11 chordoma 31.1 TP53 SERPINA3 MTAP EGFR CDKN2A CCND1
12 sarcoma 31.0 TP53 SERPINA3 MTAP IL6 CYCS CCND1
13 neurofibroma 30.9 TP53 EGFR CDKN2A
14 squamous cell carcinoma 30.9 TP53 MMP9 EGFR CDKN2A CCND1
15 fasciitis 30.8 TP53 IL6 ESR1
16 leiomyosarcoma 30.7 TP53 SERPINA3 ESR1 CDKN2A CCND1
17 adenocarcinoma 30.7 TP53 MMP9 EGFR CDKN2A CCND1
18 benign giant cell tumor 30.7 TNFSF11 SERPINA3 MMP9
19 pigmented villonodular synovitis 30.7 TP53 TNFSF11 SERPINA3 MMP9
20 fibrous histiocytoma 30.7 TP53 SERPINA3 MTAP
21 burkitt lymphoma 30.7 TP53 MIR21 IL6 CYCS CDKN2A CCND1
22 radiculopathy 30.6 IL6 CCL2 BMP2
23 bone inflammation disease 30.6 TNFSF11 SERPINA3 MMP9 MIR21 IL6 CCL2
24 osteonecrosis 30.6 TNFSF11 ESR1 BMP2
25 malignant fibrous histiocytoma 30.6 TP53 SERPINA3 MTAP
26 myxofibrosarcoma 30.6 TP53 SERPINA3 MTAP
27 hepatocellular carcinoma 30.5 TP53 SERPINA3 MMP9 MIR9-1 MIR21 IL6
28 mammary paget's disease 30.5 TNFSF11 ESR1 EGFR
29 renal cell carcinoma, nonpapillary 30.5 TP53 MMP9 MIR9-1 MIR21 GAPDH EGFR
30 adenoid cystic carcinoma 30.5 TP53 SERPINA3 MMP9 EGFR CDKN2A CCND1
31 estrogen-receptor positive breast cancer 30.5 TP53 ESR1 EGFR CCND1
32 ameloblastoma 30.5 TP53 TNFSF11 SERPINA3 MMP9
33 carcinosarcoma 30.5 TP53 EGFR CDKN2A
34 lymphoma 30.5 TP53 IL6 EGFR CDKN2A CCND1 BMI1
35 myeloma, multiple 30.5 TP53 TNFSF11 SERPINA3 MMP9 MIR9-1 MIR21
36 breast adenocarcinoma 30.4 TP53 TNFSF11 SERPINA3 MMP9 ESR1 EGFR
37 rhabdomyosarcoma 30.4 TP53 EGFR CYCS CDKN2A CCND1
38 arteriosclerosis 30.4 MMP9 MIR21 IL6 CCL2
39 meningioma, familial 30.4 TP53 SERPINA3 ESR1 EGFR CDKN2A CCND1
40 chronic kidney disease 30.4 TNFSF11 SERPINA3 MMP9 IL6 CCL2
41 oral cancer 30.4 TP53 MMP9 MIR21 EGFR CDKN2A CCND1
42 mantle cell lymphoma 30.4 TP53 IL6 GAPDH CDKN2A CCND1 BMI1
43 colon adenocarcinoma 30.4 TP53 MIR21 EGFR CYCS CCND1
44 skin carcinoma 30.4 TP53 MIR21 EGFR CDKN2A CCND1
45 peripheral nervous system disease 30.4 TRPV1 TP53 SERPINA3 MIR21 IL6 GAPDH
46 osteoporosis 30.4 TRPV1 TP53 TNFSF11 MMP9 MIR21 IL6
47 connective tissue cancer 30.4 TP53 SERPINA3 MIR9-1 MIR21 EGFR CDKN2A
48 adenosquamous carcinoma 30.4 TP53 SERPINA3 EGFR
49 pheochromocytoma 30.4 IL6 ESR1 CYCS CDKN2A CCND1
50 neuroblastoma 30.4 TP53 MMP9 MIR21 IL6 GAPDH ESR1

Graphical network of the top 20 diseases related to Bone Cancer:



Diseases related to Bone Cancer
Sources

Symptoms & Phenotypes for Bone Cancer

About this section

UMLS symptoms related to Bone Cancer:


back pain, sciatica, muscle cramp

MGI Mouse Phenotypes related to Bone Cancer:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.36 ATF3 BMP2 CCND1 CDKN2A CNR1 CYCS
2 behavior/neurological MP:0005386 10.33 ATF3 CCND1 CDKN2A CNR1 CYCS ESR1
3 homeostasis/metabolism MP:0005376 10.32 ATF3 BMP2 CCND1 CDKN2A CNR1 EGFR
4 cardiovascular system MP:0005385 10.31 BMP2 CCND1 CDKN2A CYCS EGFR ESR1
5 immune system MP:0005387 10.3 ATF3 BMP2 CCL2 CCND1 CDKN2A CYCS
6 hematopoietic system MP:0005397 10.27 ATF3 BMP2 CCND1 CDKN2A CYCS EGFR
7 integument MP:0010771 10.21 ATF3 CCND1 CDKN2A CNR1 EGFR ESR1
8 digestive/alimentary MP:0005381 10.18 BMP2 CCND1 CDKN2A CNR1 EGFR ESR1
9 adipose tissue MP:0005375 10.1 ATF3 CNR1 EGFR ESR1 IL6 TP53
10 nervous system MP:0003631 10.1 ATF3 BMP2 CCND1 CDKN2A CNR1 CYCS
11 neoplasm MP:0002006 10.07 ATF3 CCND1 CDKN2A EGFR ESR1 IL6
12 liver/biliary system MP:0005370 10.01 CDKN2A EGFR ESR1 GAPDH IL6 MTAP
13 no phenotypic analysis MP:0003012 9.86 ATF3 CDKN2A CNR1 EGFR ESR1 TNFSF11
14 reproductive system MP:0005389 9.85 BMP2 CCND1 CDKN2A CNR1 EGFR ESR1
15 respiratory system MP:0005388 9.65 ATF3 CCND1 CDKN2A EGFR ESR1 IL6
16 skeleton MP:0005390 9.4 ATF3 BMP2 CCND1 CDKN2A CNR1 CYCS
Sources

Drugs & Therapeutics for Bone Cancer

About this section

Drugs for Bone Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 214)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
2 Immunoglobulins, Intravenous Phase 4
3 Immunoglobulin G Phase 4
4 Analgesics Phase 4
5 Hormones Phase 4
6 Anti-Anxiety Agents Phase 4
7 Psychotropic Drugs Phase 4
8 Anticonvulsants Phase 4
9 Calcium, Dietary Phase 4
10 calcium channel blockers Phase 4
11
Calcium Nutraceutical Phase 4 7440-70-2 271
12 sodium fluoride Approved Phase 3 7681-49-4
13
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
14
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
15
Phenol Approved, Experimental Phase 3 108-95-2 996
16
Ethanol Approved Phase 3 64-17-5 702
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
18
Captopril Approved Phase 3 62571-86-2 44093
19
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
20
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
21
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
22
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
23
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
24
Cefazolin Approved Phase 3 25953-19-9 656510 33255
25
Etoposide Approved Phase 3 33419-42-0 36462
26
Ifosfamide Approved Phase 3 3778-73-2 3690
27 Grape Approved Phase 3
28 Cranberry Approved, Investigational Phase 3
29
Daunorubicin Approved Phase 3 20830-81-3 30323
30
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
31
Tranexamic Acid Approved Phase 3 1197-18-8 5526
32
Zoledronic Acid Approved Phase 3 118072-93-8 68740
33
Molybdenum Approved Phase 3 7439-98-7 185498
34
Etanercept Approved, Investigational Phase 2, Phase 3 185243-69-0
35
Camptothecin Experimental Phase 3 7689-03-4
36 Fluorides Phase 3
37 Listerine Phase 3
38 Mitogens Phase 2, Phase 3
39 Endothelial Growth Factors Phase 2, Phase 3
40 BB 1101 Phase 3
41 Antihypertensive Agents Phase 3
42 Diphosphonates Phase 3
43 Polymethyl Methacrylate Phase 3
44 Narcotics Phase 3
45 Analgesics, Opioid Phase 3
46
protease inhibitors Phase 3
47 HIV Protease Inhibitors Phase 3
48 Angiotensin-Converting Enzyme Inhibitors Phase 3
49
Liposomal doxorubicin Phase 3 31703
50 Alkylating Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 238)
# Name Status NCT ID Phase Drugs
1 An Open Label Study of the Efficacy, Safety, and Pharmacoeconomics of Oral Ibandronate (Bondronat 50 mg) in Treatment of Metastatic Bone Disease Completed NCT02564107 Phase 4 Ibandronate
2 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
3 Open-Label Study to Establish the Short Term Efficacy of Intravenous Loading-Doses of Bondronat 6 mg in Patients With Breast Cancer and Skeletal Metastases Experiencing Moderate to Severe Pain, Within 7 Days After Initiation of Treatment Completed NCT02553707 Phase 4 Ibandronate
4 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
5 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4 Zoledronic acid
6 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
7 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
8 A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
9 A Prospective, Single-arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis Completed NCT00334139 Phase 4 Zoledronic Acid
10 A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid and Circulating Tumor Cell Measurements in Patients With HER2-negative Metastatic Breast Cancer Without Bone Metastasis Completed NCT01129336 Phase 4 Zoledronic acid;Standard Therapy
11 A Study to Determine Correlation of MR Thermal Imaging to Actual Size of Ablation During Laser Therapy of Metastases to Bone Completed NCT00688038 Phase 4
12 Bioactive Glass Granules as Bone Graft Substitute in Filling Material of Bone Defects Completed NCT01304121 Phase 4
13 A Phase 4 Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride Recruiting NCT02312960 Phase 4
14 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Active, not recruiting NCT03301857 Phase 4 Denosumab (Cohort A)
15 Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer: A Non-inferiority, Randomized, Open, Parallel and Controlled Prospective Clinical Study Not yet recruiting NCT02480634 Phase 4 Zoledronic acid
16 A Randomized Placebo-Controlled Trial Of The Efficacy And Tolerability Of Flexibly Dosed Pregabalin In The Treatment Of Cancer-Induced Bone Pain Terminated NCT00381095 Phase 4 Pregabalin;Placebo
17 Biological Image Guided Antalgic Stereotactic Body Radiotherapy of Bone Metastases: a Randomized Phase II/III Trial Unknown status NCT01429493 Phase 2, Phase 3
18 18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques Unknown status NCT00882609 Phase 3
19 Clinical, Pathologic Characteristics and Its Mechansim of Denosumab Treated Giant Cell Tumor of Bone Unknown status NCT03259152 Phase 3 Denosumab
20 Laser Therapy Prevents Mucositis Oral in Patients Undergoing to Chemotherapy for Bone Marrow Transplantation? A Randomized Clinical Trial. Unknown status NCT02020928 Phase 3
21 Randomized, Open Label Study to Evaluate Renal Safety of Intravenous Bondronat 6 mg Infusions Over 15 Minutes Versus 60 Minutes in Patients With Metastatic Bone Disease Due to Breast Cancer Completed NCT02716792 Phase 3 Ibandronate
22 Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer Completed NCT01419717 Phase 3 Denosumab
23 A Randomized, Double-blind, Multi-centre Study to Evaluate the Fficacy and Safety of Zometa as a Treatment in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma Completed NCT00219258 Phase 3 Zoledronic acid
24 Randomized, Open Label Study to Assess the Efficacy and Safety of the Intravenous and Oral Ibandronic Acid for Improving the Performance Status of Patients With Malignant Bone Disease Secondary to Solid Tumors and Hematological Malignancies Completed NCT02561039 Phase 3 Ibandronate
25 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. Completed NCT00330759 Phase 3 Zoledronic Acid
26 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer Completed NCT00321620 Phase 3 zoledronic acid
27 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer Completed NCT00321464 Phase 3 Zoledronic Acid
28 An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma Completed NCT00950911 Phase 3 amg 162
29 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly Diagnosed Multiple Myeloma Completed NCT01345019 Phase 3 Denosumab;Zoledronic acid;Placebo to Denosumab;Placebo to zoledronic acid;Denosumab (for the open-label treatment phase)
30 Randomized Phase 2 Study on the Relationship Between Circulating VEGF and Weekly or Every-four-week Zometa in Breast Cancer Patients With Bone Metastases Completed NCT00524849 Phase 2, Phase 3 Zoledronic acid
31 A Randomized Phase III Double-Blind Study of Dexamethasone Versus Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases Completed NCT01248585 Phase 3 Dexamethasone;Placebo
32 Randomized Trial of Vertebroplasty and Radiotherapy Versus Radiotherapy Alone for Osseous Spine Metastases Completed NCT00267033 Phase 3
33 Investigation of Optimal Radiotherapy Regimen and Type of Irradiation in Treatment of Painful Bone Metastasis Completed NCT00610272 Phase 3
34 Phase III Study of Palliative Radiotherapy for Bone Metastases Comparing Single to Multiple Fractions. Completed NCT00858741 Phase 3
35 Dexamethasone for the Prevention of a Pain Flare After Palliative Radiotherapy for Painful Bone Metastases: a Multi-center Double-blind Placebo-controlled Randomized Study Completed NCT01669499 Phase 3 Dexamethasone acetate;Placebo
36 Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone: A Prospective Randomized Controlled Trial Recruiting NCT03295981 Phase 3 Zoledronic Acid
37 Phase 3 Study Evaluating Fentanyl Transmucosal in the Prevention of Pain Induced by Mobilization During Radiotherapy in Patients With Bone Metastasis Recruiting NCT02426697 Phase 3 fentanyl transmucosal;Placebo
38 Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients With Bone Metastases Recruiting NCT04307914 Phase 3
39 Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia Recruiting NCT03389724 Phase 3 Capoten®
40 Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A Multi-Center International Randomized Controlled Trial Comparing Alternative Antibiotic Regimens in Patients Undergoing Tumor Resections With Endoprosthetic Replacements Active, not recruiting NCT01479283 Phase 3 24-Hour Prophylactic Cefazolin* Antibiotic Regimen;5-Days Prophylactic Cefazolin* Antibiotic Regimen
41 A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma Active, not recruiting NCT03495921 Phase 3 Irinotecan;Temozolomide
42 A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms Active, not recruiting NCT02163226 Phase 2, Phase 3
43 Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Active, not recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Etoposide Phosphate;Ifosfamide;Vincristine;Vincristine Sulfate
44 Tranexamic Acid (TXA) to Reduce Volume Of Blood Transfused In Pediatric And Young Adult Cancer Patients Undergoing Limb Salvage Procedure Of A Lower Extremity Not yet recruiting NCT04410042 Phase 3 Tranexamic Acid
45 Postoperative Bleeding Prevention in Massive Bone Tumour Resection: a Multicentric, Randomized, Parallel, Controlled Trial to Assess the Efficacy of Tranexamic Acid Versus Evicel® and Usual Haemostasis Terminated NCT02153593 Phase 3 Tranexamic Acid;Fibrin glue
46 A Randomized, Placebo-controlled, Double-blind Study of the Effect of Bondronat Compared With Zoledronic Acid on Pain in Patients With Malignant Bone Disease Experiencing Moderate to Severe Pain Terminated NCT00099203 Phase 3 ibandronate [Bondronat];zoledronic acid
47 A Randomized, Double-blind Study of the Effect of Bondronat Compared With Zoledronic Acid on Pain in Patients With Malignant Bone Disease Experiencing Moderate to Severe Pain Terminated NCT00099177 Phase 3 ibandronate [Bondronat];zoledronic acid
48 A Cross-over Comparison of the Diagnostic Accuracy of Technetium (99mTc) Medronate Injection Prepared With 99mTc Derived From Neutron-activation Produced 99Mo Versus the Current Reference Standard of 99mTc Derived From Fission-produced 99Mo Terminated NCT03002454 Phase 3 99mTc MDP Injection:neutron-bombardment
49 A Prospective, Randomized Pilot Study of Enbrel VS Placebo in Patients Receiving Radiation Therapy to Combat Fatigue and Cachexia Terminated NCT00127387 Phase 2, Phase 3 Enbrel
50 Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions Withdrawn NCT00851162 Phase 2, Phase 3

Search NIH Clinical Center for Bone Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ZOLEDRONIC
zoledronic acid

Cochrane evidence based reviews: bone neoplasms

Sources

Genetic Tests for Bone Cancer

About this section
Sources

Anatomical Context for Bone Cancer

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Bone Cancer:

19
Bone

MalaCards organs/tissues related to Bone Cancer:

40
Bone, Breast, Prostate, Lung, Spinal Cord, Dorsal Root Ganglion, Testes
Sources

Publications for Bone Cancer

About this section

Articles related to Bone Cancer:

(show top 50) (show all 1589)
# Title Authors PMID Year
1
Long-term outcome of iliosacral resection without reconstruction for primary bone tumours. 42
32475244 2020
2
When and where do patients with bone metastases actually break their femurs? 42
32349590 2020
3
Postoperative delirium in patients undergoing surgery for bone metastases. 42
32443331 2020
4
The local and circulating SOX9 as a potential biomarker for the diagnosis of primary bone cancer. 61
32551218 2020
5
A novel immunocompetent model of metastatic prostate cancer-induced bone pain. 61
32407603 2020
6
Autophagy regulation by microRNAs: Novel insights into osteosarcoma therapy. 61
32233112 2020
7
Incidence of and risk factors for late cholecystectomy in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. 61
32422507 2020
8
Fertility in female cancer survivors: a systematic review and meta-analysis. 61
32456969 2020
9
Early urine proteome changes in an implanted bone cancer rat model. 61
31886325 2020
10
PD-1 blockade inhibits osteoclast formation and murine bone cancer pain. 61
32484460 2020
11
Comparison of Wide Margin and Inadequate Margin for Recurrence in Sacral Chordoma: A Meta-Analysis. 61
31977678 2020
12
LncRNA and mRNA expression profiles reveal the potential roles of lncRNA contributing to regulating dural penetration in clival chordoma. 61
32533822 2020
13
MiR-141-3p overexpression suppresses the malignancy of osteosarcoma by targeting FUS to degrade LDHB. 61
32484203 2020
14
The crucial p53-dependent oncogenic role of JAB1 in osteosarcoma in vivo. 61
32390003 2020
15
[Interpretation of 2020 NCCN Clinical Practice Guidelines in Oncology-Bone Cancer]. 61
32498481 2020
16
Bone Tumors: Primary Bone Cancers. 61
32573183 2020
17
Diacetoxy iodobenzene mediated regioselective synthesis and characterization of novel [1,2,4]triazolo[4,3-a]pyrimidines: apoptosis inducer, antiproliferative activities and molecular docking studies. 61
32552396 2020
18
When primary hyperparathyroidism comes as good news. 61
32554826 2020
19
Microglial Annexin A3 downregulation alleviates bone cancer-induced pain via inhibiting the Hif-1α/VEGF signaling pathway. 61
32569086 2020
20
Dual μ-opioid receptor and norepinephrine reuptake mechanisms contribute to dezocine- and tapentadol-induced mechanical antiallodynia in cancer pain. 61
32173379 2020
21
Preparation, Characterization, and Radiolabeling of [68Ga]Ga-NODAGA-Pamidronic Acid: A Potential PET Bone Imaging Agent. 61
32526838 2020
22
Bone Diseases: Current Approach and Future Perspectives in Drug Delivery Systems for Bone Targeted Therapeutics. 61
32370009 2020
23
JAK1/STAT3 regulatory effect of β-caryophyllene on MG-63 osteosarcoma cells via ROS-induced apoptotic mitochondrial pathway by DNA fragmentation. 61
32359221 2020
24
The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice. 61
32403415 2020
25
Apatinib ameliorates doxorubicin-induced migration and cancer stemness of osteosarcoma cells by inhibiting Sox2 via STAT3 signalling. 61
32440509 2020
26
Squamous cell carcinoma of the ear canal infiltrating the temporal bone: A case report. 61
32376194 2020
27
Combinational delivery of anticancer drugs for osteosarcoma treatment using electrosprayed core shell nanocarriers. 61
32367204 2020
28
CDKL3 promotes osteosarcoma progression by activating Akt/PKB. 61
32234750 2020
29
Wogonin Influences Osteosarcoma Stem Cell Stemness Through ROS-dependent Signaling. 61
32354895 2020
30
circStrn3 is involved in bone cancer pain regulation in a rat model. 61
32395748 2020
31
Lemairamin, isolated from the Zanthoxylum plants, alleviates pain hypersensitivity via spinal α7 nicotinic acetylcholine receptors. 61
32184015 2020
32
An understanding of bone pain: A narrative review. 61
32062002 2020
33
A Novel 3D Bioprinter Using Direct-Volumetric Drop-On-Demand Technology for Fabricating Micro-Tissues and Drug-Delivery. 61
32423161 2020
34
Dual-targeting liposome modified by glutamic hexapeptide and folic acid for bone metastatic breast cancer. 61
32017901 2020
35
En Bloc Subtotal Temporal Bone Resection in a Case of Advanced Ear Cancer: 2-Dimensional Operative Video. 61
32409835 2020
36
The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis. 61
32326412 2020
37
The impact of bone cancer on the peripheral encoding of mechanical pressure stimuli. 61
32301838 2020
38
Brachyury: Strategies for Drugging an Intractable Cancer Therapeutic Target. 61
32209441 2020
39
Fibroblastic Subtype has a Favourable Prognosis in Appendicular Osteosarcoma of Dogs. 61
32359626 2020
40
Tripartite motif-containing 46 promotes viability and inhibits apoptosis of osteosarcoma cells by activating NF-κB signaling through ubiquitination of PPARα. 61
32295675 2020
41
Modified Nanoparticles as Potential Agents in Bone Diseases: Cancer and Implant-Related Complications. 61
32244745 2020
42
Effect of Regiochemistry and Methylation on the Anticancer Activity of a Ferrocene-Containing Organometallic Nucleoside Analogue. 61
32255248 2020
43
Comparison of methods for the isolation of cell-free DNA from cell culture supernatant. 61
32338581 2020
44
Baicalein nanofiber scaffold containing hyaluronic acid and polyvinyl alcohol: preparation and evaluation. 61
32283911 2020
45
Non-melanoma skin cancer as a clinical marker for internal malignancies: a nationwide population-based cohort study. 61
31494979 2020
46
A Novel Mechanism of BAM8-22 Inhibiting Microglia Activation: Represses CX3CR1 Expression via Upregulating miR-184. 61
31833017 2020
47
[Early intervention of bone-nearby acupuncture combined with electroacupuncture on morphine tolerance in bone cancer pain rats and its effect on the expression of HDAC and MOR in dorsal root ganglia]. 61
32275370 2020
48
Suppression of histone deacetylases by SAHA relieves bone cancer pain in rats via inhibiting activation of glial cells in spinal dorsal horn and dorsal root ganglia. 61
32321538 2020
49
Hierarchical porous Mg2SiO4-CoFe2O4 nanomagnetic scaffold for bone cancer therapy and regeneration: Surface modification and in vitro studies. 61
32228948 2020
50
Alendronic Acid as Ionic Liquid: New Perspective on Osteosarcoma. 61
32213930 2020
Sources

Variations for Bone Cancer

About this section

Copy number variations for Bone Cancer from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 70082 12 58138784 58142025 Amplification SAS Bone cancer
2 70083 12 58141509 58146230 Amplification CDK4 Bone cancer
3 71134 12 67700000 68661632 Amplification MDM2 Bone cancer
Sources

Expression for Bone Cancer

About this section
Search GEO for disease gene expression data for Bone Cancer.
Sources

Pathways for Bone Cancer

About this section

Pathways related to Bone Cancer according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.75 TP53 TNFSF11 IL6 ESR1 EGFR CYCS
2
Cytokine Signaling in Immune system 65
Show member pathways
 13.33 TP53 TNFSF11 MMP9 IL6 EGFR CCND1
3
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.02 TP53 MMP9 IL6 EGFR CYCS CCND1
4
TNFR1 Pathway 63
Show member pathways
 12.99 TP53 TNFSF11 MMP9 IL6 EGFR CYCS
5
Human cytomegalovirus infection 36
Show member pathways
 12.86 TP53 IL6 EGFR CYCS CDKN2A CCND1
6
Endometrial cancer 36
Show member pathways
 12.83 TP53 MMP9 EGFR CYCS CDKN2A CCND1
7
Measles 36
Show member pathways
 12.79 TP53 IL6 CYCS CCND1 CCL2
8
Gastric cancer 36
Show member pathways
 12.73 TP53 TNFSF11 ESR1 EGFR CDKN2A CCND1
9
Glioma 36
Show member pathways
 12.62 TP53 MMP9 ESR1 EGFR CDKN2A CCND1
10
DNA Damage Response 1
Show member pathways
 12.35 TP53 CYCS CDKN2A CCND1
11
Pathways in cancer 36
12.33 TP53 MMP9 IL6 ESR1 EGFR CYCS
12
Human T-cell leukemia virus 1 infection 36
12.31 TP53 IL6 CDKN2A CCND1
13
Folate Metabolism 1
Show member pathways
 12.3 TP53 SERPINA3 IL6 CCL2
14
Translation Non-genomic (rapid) action of Androgen Receptor 22
Show member pathways
 12.29 TP53 IL6 EGFR CCND1 BMP2
15
Transcriptional misregulation in cancer 36
12.22 TP53 MMP9 IL6 BMI1
16
Proteoglycans in cancer 36
12.16 TP53 MMP9 MIR21 ESR1 EGFR CCND1
17
Cellular senescence (KEGG) 36
12.11 TP53 IL6 CDKN2A CCND1
18
Colorectal Cancer Metastasis 63
12.11 TP53 MMP9 IL6 EGFR CCND1
19
Integrated Breast Cancer Pathway 1
12.1 TP53 ESR1 EGFR CCND1
20
Alzheimers Disease 1
12.05 TP53 MIR9-1 MIR21 GAPDH CYCS
21
Glioblastoma Multiforme 63
11.94 TP53 EGFR CDKN2A CCND1
22
Interleukin-4 and 13 signaling 65
11.91 TP53 MMP9 IL6 CCND1 CCL2
23
Senescence and Autophagy in Cancer 1
11.86 TP53 IL6 CDKN2A BMP2 BMI1
24
Validated targets of C-MYC transcriptional activation 1
11.77 TP53 MMP9 GAPDH BMI1
25
MicroRNAs in cancer 36
11.72 TP53 MMP9 MIR9-1 MIR21 EGFR CDKN2A
26
Platinum drug resistance 36
11.71 TP53 CYCS CDKN2A
27
Spinal Cord Injury 1
11.71 TP53 MMP9 IL6 EGFR CCND1 CCL2
28
Transcription Ligand-dependent activation of the ESR1/SP pathway 22
Show member pathways
 11.69 ESR1 EGFR CCND1
29
Transcription_P53 signaling pathway 22
11.66 TP53 CDKN2A BMP2 ATF3
30
Regulation of Telomerase 1
11.65 ESR1 EGFR CCND1
31
AGE/RAGE pathway 1
11.65 MMP9 EGFR CYCS
32
LPA receptor mediated events 1
11.64 MMP9 IL6 EGFR
33
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.62 MMP9 IL6 CCND1
34
Lung fibrosis 1
11.62 MMP9 IL6 CCL2
35
Bladder cancer 36 1
11.58 TP53 MMP9 EGFR CDKN2A CCND1
36
ATF-2 transcription factor network 1
11.55 IL6 CCND1 ATF3
37
Hepatitis C and Hepatocellular Carcinoma 1
11.51 TP53 IL6 CCND1
38
Photodynamic therapy-induced AP-1 survival signaling. 1
11.36 TP53 IL6 EGFR CDKN2A CCND1
39
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.24 MMP9 IL6 CCND1 CCL2
40
Immune response_Oncostatin M signaling via JAK-Stat in human cells 22
11.02 SERPINA3 CCND1 CCL2
Sources

GO Terms for Bone Cancer

About this section

Cellular components related to Bone Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear membrane GO:0031965 8.92 TP53 GAPDH EGFR CCND1

Biological processes related to Bone Cancer according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.03 TP53 TNFSF11 IL6 ESR1 EGFR CDKN2A
2 positive regulation of transcription, DNA-templated GO:0045893 10 TP53 IL6 ESR1 EGFR CDKN2A BMP2
3 negative regulation of transcription by RNA polymerase II GO:0000122 10 TRPV1 TP53 ESR1 CCND1 BMP2 BMI1
4 inflammatory response GO:0006954 9.97 TRPV1 SERPINA3 IL6 CCL2 BMP2
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 MIR21 EGFR CCL2 BMP2
6 negative regulation of cell proliferation GO:0008285 9.88 TP53 MIR9-1 MIR21 IL6 CDKN2A BMP2
7 positive regulation of protein kinase B signaling GO:0051897 9.85 TNFSF11 MIR21 ESR1 EGFR
8 cellular response to growth factor stimulus GO:0071363 9.79 TRPV1 EGFR BMP2
9 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.77 MIR21 CDKN2A CCL2
10 positive regulation of osteoblast differentiation GO:0045669 9.76 MIR21 IL6 BMP2
11 sensory perception of pain GO:0019233 9.73 TRPV1 CNR1 CCL2
12 positive regulation of protein phosphorylation GO:0001934 9.72 MMP9 MIR21 EGFR CCND1 BMP2
13 positive regulation of fibroblast proliferation GO:0048146 9.71 ESR1 EGFR BMI1
14 monocyte chemotaxis GO:0002548 9.69 TNFSF11 IL6 CCL2
15 positive regulation of epithelial to mesenchymal transition GO:0010718 9.67 MIR21 IL6 BMP2
16 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress GO:1990440 9.64 TP53 ATF3
17 regulation of neuroinflammatory response GO:0150077 9.63 MMP9 IL6
18 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.63 TP53 ESR1
19 cytokine-mediated signaling pathway GO:0019221 9.63 TP53 TNFSF11 MMP9 IL6 CCND1 CCL2
20 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.62 TP53 ESR1
21 mammary gland epithelial cell proliferation GO:0033598 9.61 TNFSF11 CCND1
22 mitotic G1 DNA damage checkpoint GO:0031571 9.6 TP53 CCND1
23 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.58 MIR21 IL6
24 mammary gland alveolus development GO:0060749 9.54 TNFSF11 ESR1 CCND1
25 positive regulation of gene expression GO:0010628 9.5 TP53 TNFSF11 MIR21 IL6 CDKN2A BMP2
26 response to UV-A GO:0070141 9.48 EGFR CCND1
27 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.43 TP53 IL6 EGFR
28 positive regulation of apoptotic process GO:0043065 9.23 TRPV1 TP53 MMP9 MIR21 IL6 CNR1

Molecular functions related to Bone Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.21 TRPV1 TP53 TNFSF11 SERPINA3 MTAP MMP9
2 protein kinase binding GO:0019901 9.77 TP53 ESR1 EGFR CDKN2A CCND1
3 cytokine activity GO:0005125 9.62 TNFSF11 IL6 CCL2 BMP2
4 identical protein binding GO:0042802 9.28 TRPV1 TP53 TNFSF11 MMP9 GAPDH ESR1
5 nitric-oxide synthase regulator activity GO:0030235 9.16 ESR1 EGFR
6 disordered domain specific binding GO:0097718 9.13 TP53 GAPDH CDKN2A
Sources

Sources for Bone Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....